Among patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations, nearly half (48.8%) did not receive a PARP inhibitor, despite recent FDA approvals and recent trials ...
Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval, making it the first precision medicine combo for patients with BRCA2-mutated metastatic ...
Rubraca is now FDA-approved for BRCA mutation-associated mCRPC after prior androgen receptor-directed therapy, confirming its efficacy in the TRITON3 trial. The TRITON3 trial showed Rubraca ...
Please provide your email address to receive an email when new articles are posted on . Nearly half of men with metastatic castration-resistant prostate cancer eligible for PARP inhibitors do not get ...
How HRD and BRCA results steer frontline ovarian cancer maintenance—niraparib vs olaparib—plus guidance on recurrence, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results